Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)

NCT06017869 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Mitochondrial Diseases
Pearson Syndrome

Interventions

BIOLOGICAL: MNV-201

Sponsor

Minovia Therapeutics Ltd.